Pharmacological notes about trans­sexualism

Terminology and concepts

We define “transsex” as the people who undergo a treatment to change their sexually dimoprhic features to resemble the other sex. The word “transsexual” is widespread for the same meaning; we prefer the term “transsex” to emphasize that it is about sexual dimorphism, not sexuality. We use the word “transsexualism” to refer to this phenomenon. We refer to people who are not transsex as “cissex” or just “cis”. This text concerns exclusively male to female transsex people. Male to female transsex people (MTFs) are also called trans women.

Hormone replacement treatment

For an overview at the endocrinological level of the signaling pathway responsible for progestogens, androgens and estrogens, see Golan et al. (2017) chapter 30 “Pharmacology of Reproduction”; this is required knowledge for any transsexual.

The main source of endogenous androgens in biological males are the testis. Additionally, in both sexes the adrenal glands secrete androgens. The main androgen produced by testis is testosterone. The enzymes 5α-reductases converts testosterone into 4,5-dihydrotestosterone (common abbreviation: DHT). DHT is a more potent androgen than testosterone, thus the effect of 5α-reductases is to amplify the action of testosterone selectively in the cells where it is expressed and unselectively by increasing circulating DHT. 5α-reductases are highly expressed in cells of the male reproductive system. There are 2 known types of 5α-reductases in humans. 5α-reductase type I (gene SRD5A1) is expressed in the liver and nongenital skin (among other tissues) and 5α-reductase type II (gene SRD5A2) is expressed in the prostate and genital skin (among other tissues). There are other genes classified under the SRD5A family that appear to not to participate in steroid metabolism (Stiles 2010); in specific Chávez (2015) found that the so-called “5α-reductase type III” (gene SRD5A3) does not act as a 5α-reductase in humans, i.e.: does not convert testosterone into DHT.

The synthesis of androgens in the testicles requires the presence of circulating lutenizing hormone (LH). Lutenizing hormone is a protein secreted by the hypophysis. Lutenizing hormone (LH) and follicle stimulating hormone (FSH) are collectively referred to as the gonadotropins. The production of adrenal androgens is not dependant on gonadoptropins.

Tebbens et al. 2019 examined quantitatively changes in facial dimensions on HRT with measurements taken over the skin; they found that HRT changes sexually dimoprhic dimensions towards female (see the paper for quantitative data).

Kranz et al. (2014) found that HRT decreases expression of the serotonin transporter in MTF transsexuals. Thus it is inferred, HRT has a similar effect to a serotonin reuptake inhibitor and increases the concentration of available serotonin.

In a review about multiple orgasms in biological males Wibowo, Wassersug (2016) mention that ejaculation and exposure to androgens may be at least in part responsible for the post-ejaculatory refractory period and thus the inability to have multiple orgasms in one sexual session in cis men. Kinsey (mentioned in Wibowo, Wassersug 2016) reported that among young males, capacity for multiple penile orgasms are more prevalent in kids and teens. Warkentin et al. (2016) reported a case of a prostate cancer patient who became penile-multi-orgasmic on anti-androgen treatment.

Leinung et al. (2018) studied the effect of estradiol alone, with spironolactone, and with finasteride on estradiol and testosterone levels. They found that oral estradiol slightly suppresses androgens. However, they found that administering estradiol together with either spironolactone or finasteride increases the level of testosterone compared to the same dose of oral estradiol alone.

Reviews of the pharmaceuticals used for HRT and its effects include Tangpricha, den Heijer (2016).


This section assumes basic knowledge of the hypothalamus-hypophysis-gonads axis from the reader, only a very succint review is given next. In a physiologically normal human, the hypthalamus secretes gonadotrpoin releasing hormone (GnRH) in slow pulses. The pulses of GnRH causes the hypophysis to secrete lutenizing hormone (LH) and follicle-stimulating hormone (FSH). In both sexes LH and FSH are necessary for the normal functioning of the reproductive system and for fertility. LH stimulates synthesis of testosterone in ovaries and testicles. For a more detailed summary see chapters previously mentioned in the book of Golan et al. (2017). For details on the chemical structure and pharmacodynamics of GnRH, LH and FSH, see Kleine, Rossmanith (2016).

Anti-androgens work by interfering with at least one step of the hypothalamus-hypophysis-gonads system or by preventing androgens from acting on the androgen receptor by competitive inhibition (silent antagonist). More specifically their mechanism of action may be classified as follow (categories are not mutually exclusive):

Cyproterone acetate (common abbreviation: CPA) is the anti-androgen par excellence for male to female hormone replacement therapy (MTF HRT). CPA is a progestogen. Like other progestogens, it suppresses secretion of gonadotropins and thus of gonadal androgens. Additionally it acts as a partial agonist of the androgen receptor. Fung et al. (2017) found that a dose of 25 mg/d is sufficient to suppress testosterone in MTF transsexuals to below cis female levels. See Neuman (1994) for an account of the development and pharmacology of cyproterone acetate and of progestogens in general. Another review of the pharmacology of progestogens is Schindler et al. (2013).

Medroxyprogesterone acetate (common abbreviation: MPA) is an anti-androgen of the progestogen class. It is commonly available as solutions for depot injections and oral tablets. Johanson et al. (1986) investigated the pharmacokinetics of MPA on humans via oral intake. They found a half-life of 40 h to 60 h.

Spironolactone should not be used as an anti-androgen and is mentioned here only as an advertence. Spironolactone is a mineralocorticoid duiretic with weak progestogen activity which has been misused as an anti-androgen, especially in the United States. Liang et al. (2018) found that a HRT regime of oral estradiol and spironolactone failed to supress testosterone in the top quartile of biological males per pre-treatment level of testosterone. Leinung et al. (2018) found that estradiol alone suppresses testosterone better than if combined with spironolactone.


The main estrogens in cis women are estradiol, estrone and estriol, of which estradiol is the most potent. The commonly used estrogens for MTF transsex people are estradiol (17β-estradiol), 17β-esters of estradiol and ethynylestradiol.

17β-esters and occasionally 3-esters of estradiol are the common active compounds used for depot injection; these are pro-drugs that are convereted to estradiol within the body. The longer the ester chain, the slower the pharmacokinetics (longer time to peak dose and longer half life). Oriowo et al. (1980) compared the pharmacokinetics of 3 esters of estradiol administered as intramuscular depot injections with arachis oil as the carrier. They found the time to peak blood concentration as follows: estradiol benzoate: 1.8 d, estradiol valerate: 2.2 d, estradiol cypionate: 3.9 d. Garza-Flores (2014) compared the pharmacokinetics of 3 esters of estradiol again administered as depot injections. He found the time to peak blood concentration of estradiol to be as follows: estradiol valerate: 2 d, estradiol cypionate: 4 d, estradiol enanthate: 6.5 d, 8.1 d (the 2 numbers are for different medical centers).

Kuhl (2005) found that ethynylestradiol is 120 times as potent as estradiol compared on a mass basis, oral administration. Note that an higher potency is not an indicative that the substance is more effective, only that a lower dose will be required for a similar effect. Lübbert et al. (1992) found ethynylestradiol to be effective in reducing gonadotropins and testosterone to below-castrate levels in an experiment done in a single healthy male. This suggests that when an high-enough dose is used for MTF HRT no additional anti-androgen is needed. Jain et al. (2006) report Kd(ethynylestradiol-human ERα) = 2.0 nmol/L, Kd(ethynylestradiol-human ERβ) = 8.1 nmol/L

Wibowo, Wassersug (2013) found that estrogens increase sexual interest in biological males.

Schneider et al. (2017) examined the effects of HRT on testicular tissue and function.

Harrison et al. (2014) found that 17α-estradiol (an isomer of 17β-estradiol with diminished estrogenic potency) prolonges lifespan in a study with mice.

Estrogens are known to be responsible for the cessation of grow in height in both males and females. Therefore, transsexuals should not use estrogens until they reach their desired height or until ephyphyseal plates have ossified (because after ossification, there is no prospect of natural vertical growth). See Chagin, Sävendahl (2007). Transsex people and other people who desire a higher height but have already ossified growth disks can opt for limb lengthening by the method of distraction osteogenesis. This method was pioneered in the USSR by Gavriil Ilizarov. For small increments in height, the procedure can involve exclusively lengthening the femur. For higher increases, the femur, tibia, and peroné are lengthened, and optionally the arms for the sake of proportions. A full discussion of limb lengthening is beyond the scope of this text.

Giltay, Gooren (2000) studied the effect of HRT in production of body hair and skin oil (sebum). They found that “The hair diameter fell sharply within 4 months and remained rather constant thereafter, whereas the median growth rate and density on the cheek and upper abdomen dropped only slowly but progressively”. In other words, HRT will not make beard and mustache disappear; for that, temporary or permanent hair removal procedures like waxing, plucking, laser, intense pulsed light or electrolysis should be used. The same study found that production of skin oil decreased and was already very little after 4 months of HRT.

A common side effect of HRT is lowered libido. Depending on the user this may be a desirable or undesirable effect. If the user wishes to increase libido to pre-HRT levels or higher, bupropion can be used. Crenshaw et al. (1987) found bupropion to be effective in raising libido in cis males and cis females.

Selective estrogen receptor modulators

In a study on old post-menopausal women (56 to 66 years old) Francucci et al. 2005 found that raloxifene causes a change towards a female pattern of fat distribution.


Prolactin is an endogenous protein secreted by the hypophysis. Prolactin promotes the secretion of milk. Dopamine receptor agonists like cabergoline, bromocriptine and pramipexole can be used to reduce prolactin.

Melanogenesis inhibitors (skin whitening agents)

Statistically, women tend to have a lighter skin color than men. Variation in skin color, hair color and eye color is mostly because of the dark-colored proteins called generically “melanin”. Pigments acquired through food and embedded within the skin and also blood vessels play a minor role. Given that skin color is sexually dimorphic to some degree, and a ligher skin color is more aesthetically desirable, skin whitening is a complement –not a substitute– for manipulaion of one’s primary sex hormones. Anecdotally, many transsexuals (including the author) with light skin report to have experienced further lightening concurrent with starting HRT. It can be conjectured that HRT has overall a skin whitening effect, but it could also be attributed to confounders (i.e.: spending more time indoors and under shadow).

There exist a big set of known substances that inhibit the pigmentation of skin with melanin which we call “melanogenesis inhibitors”. There are several mechanism of actions of melanogenesis inhibitors; for a review, see Pillaiyar et al. (2017), Chang (2012) and Ebanks et al. (2009). The molecular pathway of melanogenesis is well-understood; a detailed treatment is outside the scope of this article.

Several products are commercially available for skin whitening, some are taken orally or injected and have a systemic effect; others are topical. Only agents known to be commercially available for systemic effect are mentioned next. Hesperidin is an anti-oxidant; suppression of melanogenesis was examined in-vitro by Lee et al. (2016). Glutathione administered orally was examined in-vivo in humans in Arjinpathana, Asawanonda (2012). Glutathione is also commercially available as injections. For a review of glutathione see Villarama, Mailbach (2005) and Sonthalia et al. (2016, 2018). Luteolin was examined in-vitro by Choi et al. (2008).

There are irreversibly inhibitors of tyrosinase described in the literature. These have the potential to be very effective for skin whitening, and hair lightening, to the point of virtually complete elimination of melanin. Unfortunately, as of 2019 none of these agents are commercially available as far as it is known to the author.


N. Arjinpathana, P. Asawanonda (2012) “Glutathione as an oral whitening agent: A randomized, double-blind,placebo-controlled study”. DOI: 10.3109/09546631003801619.

A. S. Chagin, L. Sävendahl (2007) “Oestrogen receptors and linear bone growth”. DOI: 10.1111/j.1651-2227.2007.00415.x.

T. Chang (2012) “Natural Melanogenesis Inhibitors Acting Through the Down-Regulation of Tyrosinase Activity”. DOI:

B. Chávez et al. (2015) “Hamster SRD5A3 lacks steroid 5α-reductase activity in vitro”. DOI: 10.1016/j.steroids.2014.11.005.

M. Y. Choi et al. (2008) “Whitening Activity of Luteolin Related to the Inhibition of cAMP Pathway in α-MSH-stimulated B16 Melanoma Cells”. DOI: 10.1007/s12272-001-1284-4.

T. L. Crenshaw et al. (1987) “Pharmacologic modification of psychosexual dysfunction”. DOI: 10.1080/00926238708403896.

J. P. Ebanks et al. “Mechanisms Regulating Skin Pigmentation: The Rise and Fall of Complexion Coloration”. DOI: 10.3390/ijms10094066.

C. M. Francucci et al. (2005) “Effects of raloxifene on body fat distribution and lipid profile in healthy post-menopausal women”. DOI: 10.1007/BF03347261.

R. Fung et al. (2017) “Is a lower dose of cyproterone acetate as effective at testosterone suppression in transgender women as higher doses?”. DOI: 10.1080/15532739.2017.1290566.

E. J. Giltay, L. J. G. Gooren (2000) “Effects of Sex Steroid Deprivation/Administration on Hair Growth and Skin Sebum Production in Transsexual Males and Females”. DOI: 10.1210/jcem.85.8.6710.

D. E. Golan et al. (2017) “Principles of Pharmacology: The Patophysiologic Basis of Drug Therapy”, 4th ed. ISBN: 9781451191004.

L. G. Hamann et al. (1998) “Synthesis and Biological Activity of a Novel Series of Nonsteroidal, Peripherally Selective Androgen Receptor Antagonists Derived from 1,2-Dihydropyridono[5,6-g]quinolines”. DOI: 10.1021/jm970699s.

D. E. Harrison et al (2014) “Acarbose, 17α-estradiol, and nordihydroguaiaretic acid extend mouse lifespan preferentially in males”. DOI: 10.1111/acel.12170.

N. Jain et al. (2006) “Novel Chromene-Derived Selective Estrogen Receptor Modulators Useful for Alleviating Hot Flushes and Vaginal Dryness”. DOI: 10.1021/jm060353u, (supporting information).

E. D. B. Johansson et al. (1986) “Medroxyprogesterone Acetate Pharmacokinetics Following Oral High-Dose Administration in Humans: A Bioavailability Evaluation of a New MPA Tablet Formulation”. DOI: 10.1111/j.1600-0773.1986.tb00115.x.

B. Kleine, W. G. Rossmanith (2016) “Hormones and the Endocrine System”. DOI: 10.1007/978-3-319-15060-4. ISBN: 978-3-319-15059-8, 978-3-319-15060-4.

G. S. Kranz et al. (2014) “High-Dose Testosterone Treatment Increases Serotonin Transporter Binding in Transgender People”. DOI: 10.1016/j.biopsych.2014.09.010.

H. Kuhl (2005) “Pharmacology of estrogens and progestogens: influence of different routes of administration”. DOI: 10.1080/13697130500148875.

H. J. Lee et al. “Hesperidin, A Popular Antioxidant Inhibits Melanogenesis via Erk1/2 Mediated MITF Degradation”. DOI: 10.3390/ijms160818384.

J. J. Liang et al. (2018) “Testosterone levels achieved by medically treated transgender women in a United States endocrinology clinic”. DOI: 10.4158/EP-2017-0116.

M. C. Leinung et al. (2018) “Hormonal Treatment of Transgender Women with Oral Estradiol”. DOI: 10.1089/trgh.2017.0035. Open access.

H. Lübbert et al. (1992) “Effects of ethinyl estradiol on semen quality and various hormonal parameters in a eugonadal male”. DOI: 10.1016/s0015-0282(16)55271-6.

M. Tebbens et al. (2019) “Gender-Affirming Hormone Treatment Induces Facial Feminization in Transwomen and Masculinization in Transmen: Quantification by 3D Scanning and Patient-Reported Outcome Measures”. DOI: 10.1016/j.jsxm.2019.02.011.

F. Neuman (1994) “The antiandrogen cyproterone acetate: discovery, chemistry, basic pharmacology, clinical use and tool in basic research”. DOI: 10.1055/s-0029-1211261.

M. A. Oriowo, et al. (2008) “A comparison of the pharmacokinetic properties of three estradiol esters”. DOI: 10.1016/s0010-7824(80)80018-7.

J. Garza-Flores (1994) “Pharmacokinetics of once-a-month injectable contraceptives”. DOI: 10.1016/0010-7824(94)90032-9.

T. Pillaiyar et al. (2017) “Downregulation of melanogenesis: drug discovery and therapeutic options”. DOI: 10.1016/j.drudis.2016.09.016.

A. E. Schindler et al (2003) “Classification and pharmacology of progestins”. DOI: 10.1016/j.maturitas.2003.09.014.

F. Schneider et al (2017) “Andrology of male-to-female transsexuals: influence of cross-sex hormone therapy on testicular function”. DOI: 10.1111/andr.12405.

S. Sonthalia et al. (2016) “Glutathione as a skin whitening agent: Facts, myths, evidence and controversies”. DOI: 10.4103/0378-6323.179088.

S. Sonthalia et al. (2018) “Glutathione for skin lightening: a regnant myth or evidence-based verity?”. DOI: 10.5826/dpc.0801a04.

A. L. Stiles, D. W. Russell (2010) “SRD5A3: A Surprising Role in Glycosylation”. DOI: 10.1016/j.cell.2010.07.003.

V. Tangpricha, M. den Heijer (2016) “Oestrogen and anti-androgen therapy for transgender women”. DOI: 10.1016/S2213-8587(16)30319-9. Free authors’ manuscript in PMC.

H. van Poppel, S. Nilsson (2008) “Testosterone Surge: Rationale for Gonadotropin-Releasing Hormone Blockers?”. DOI: 10.1016/j.urology.2007.12.070.

C. D. Villarama, H. I. Maibach “Glutathione as a depigmenting agent: an overview”. DOI: 10.1111/j.1467-2494.2005.00235.x.

K. Warkentin et al. (2006) “Restoration of Satisfying Sex for a Castrated Cancer Patient with Complete Impotence: A Case Study”. DOI: 10.1080/00926230600835346.

E. Wibowo, R. Wassersug (2013) “The effect of estrogen on the sexual interest of castrated males: Implications to prostate cancer patients on androgen-deprivation therapy”. DOI: 10.1016/j.critrevonc.2013.01.006.

E. Wibowo, R. Wassersug (2016) “Multiple Orgasms in Men—What We Know So Far”. DOI: 10.1016/j.sxmr.2015.12.004.

If you found this information useful please consider donating bitcoins. Address: 16CcLt78dHAfdAGSmxCnthWemJ42i9eptb.